Latest filing published 12 Nov 2025 for Annovis Bio, Inc., €172k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -56.3%Entry US$2.29 · Close 23 Oct 2026 US$1.00
- -59.4%Entry US$30.81 · Close at T+365 US$12.50
- +175.3%Entry US$6.16 · Close at T+365 US$16.96
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Maria-Luisa Maccecchini: trading record in brief
Maria-Luisa Maccecchini is a declared insider at 2 companies (chief executive); the most frequent names are Annovis Bio, Inc. and CALMARE THERAPEUTICS Inc. Over a trading history stretching from 4 January 2006 to 28 October 2025, the count stands at 19 filings.
The open-market record is one-sided, with 5 purchases worth €617k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 6 share grants and 2 option exercises. In 2025 alone, the filings show 1 purchase and no sales.
Half of the purchases are above €8,704 and half below. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 33% of cases; the median change was -40.4%. Past outcomes like these are no guarantee of what comes next.
On 12 November 2025 came the latest disclosure, an open-market purchase for €172k in Annovis Bio, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Maria-Luisa Maccecchini
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 97,561 shares@ US$2.0511.9% of flowCommon StockSEC:0001104659-25-109906:0Canonical exit: 26 Jan 2026 (T+90)
- 46,000 shares@ US$3.379.4% of flowCommon StockSEC:0001104659-25-056578:0
- 10,000 shares0Common StockSEC:0001104659-24-077834:0
- 10,000 shares0Common StockSEC:0001104659-24-077834:1
- 10,000 shares0Common StockSEC:0001104659-24-077834:2
- 40,970 shares@ US$6.1015.9% of flowCommon StockSEC:0001104659-23-120762:0
- 41,186 shares@ US$6.0715.9% of flowCommon StockSEC:0001104659-23-120302:0
- 3,000 shares0Common StockSEC:0001104659-23-050393:0
- 20,000 shares@ US$12.6116.1% of flowCommon StockSEC:0001104659-23-044202:0
- 52,755 shares@ US$0.140.5% of flowCommon StockSEC:0001104659-23-014610:0
- 32,959 shares@ US$0.140.3% of flowCommon StockSEC:0001104659-22-005059:0
- 18,000 shares@ US$27.6129.9% of flowCommon StockSEC:0001415889-21-004862:0Canonical exit: 9 Jan 2022 (T+90)
- 1,600 shares@ US$6.000.6% of flowCommon StockSEC:0001104659-20-010939:0Canonical exit: 30 Apr 2020 (T+90)
- 7,937 sharesCommon StockSEC:0001104659-20-010939:1
- 762,896 sharesCommon StockSEC:0001104659-20-010939:2
- 2,500 shares0Common StockSEC:0001315018-07-000001:0
- 200 shares@ US$3.98Common StockSEC:0001315018-06-000001:0Canonical exit: 4 Apr 2006 (T+90)
- 1,800 shares@ US$4.00Common StockSEC:0001315018-06-000001:1Canonical exit: 4 Apr 2006 (T+90)
- 2,500 shares0Common StockSEC:0001144204-06-000349:0
19 of 19 declarations